In silico screening of mutated K-ras inhibitors from malaysian Typhonium flagelliforme for non-small cell lung cancer

Advances in Bioinformatics

Volumn 2014, Issue , 2014, Pages

  Fatima, Ayesha ^a   Yee, H F ^a  

^a UCSI UNIVERSITY   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

TYPHONIUM FLAGELLIFORME;

EID: 84911866065     PISSN: 16878027     EISSN: 16878035     Source Type: Journal    
DOI: 10.1155/2014/431696     Document Type: Article

References (36)

1. Omar Z. A., Ali Z. M., Tamin Nor S. I., Malaysian Cancer Statistics-Data and Figure Penisular Malysia 2006 National Cancer Registry Ministry of Health Malaysia
2. National Cancer Society Malaysia,. http://cancer.org.my/learn-about-cancer/about-cancer/
3. Lim G. C. C., Overview of cancer in Malaysia. Japanese Journal of Clinical Oncology 2002 32 S37 S42 10.1093/jjco/hye132 2-s2.0-0036516609
4. Mohan S., Abdelwahab S. I., Cheah S.-C., Apoptosis effect of girinimbine isolated from Murraya koenigii on lung cancer cells in vitro. Evidence-based Complementary and Alternative Medicine 2013 2013 12 689865 10.1155/2013/689865 2-s2.0-84876572461
5. Liam C.-K., Wahid M. I. A., Rajadurai P., Cheah Y.-K., Ng T. S.-Y., Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients. Journal of Thoracic Oncology 2013 8 6 766 772 10.1097/JTO.0b013e31828b5228 2-s2.0-84879501751
6. The American Cancer Society, Learn about cancer. http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer
7. Fernández-Medarde A., Santos E., Ras in cancer and developmental diseases. Genes and Cancer 2011 2 3 344 358 10.1177/1947601911411084 2-s2.0-79960052850
8. Westcott P. M. K., To M. D., The genetics and biology of KRAS in lung cancer. Chinese Journal of Cancer 2013 32 2 63 70 10.5732/cjc.012.10098 2-s2.0-84873660518
9. Milburn M. V., Tong L., Devos A. M., Brünger A., Yamaizumi Z., Nishimura S., Kim S.-H., Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 1990 247 4945 939 945 10.1126/science.2406906 2-s2.0-0025117674
10. Eberhard D. A., Johnson B. E., Amler L. C., Goddard A. D., Heldens S. L., Herbst R. S., Ince W. L., Jänne P. A., Januario T., Johnson D. H., Klein P., Miller V. A., Ostland M. A., Ramies D. A., Sebisanovic D., Stinson J. A., Zhang Y. R., Seshagiri S., Hillan K. J., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology 2005 23 25 5900 5909 10.1200/JCO.2005.02.857 2-s2.0-24944497744
11. Brünger A. T., Milburn M. V., Tong L., DeVos A. M., Jancarik J., Yamaizumi Z., Nishimura S., Ohtsuka E., Kim S.-H., Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain. Proceedings of the National Academy of Sciences of the United States of America 1990 87 12 4849 4853 10.1073/pnas.87.12.4849 2-s2.0-0025327522
12. Massarelli E., Varella-Garcia M., Tang X., Xavier A. C., Ozburn N. C., Liu D. D., Bekele B. N., Herbst R. S., Wistuba I. I., KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clinical Cancer Research 2007 13 10 2890 2896 10.1158/1078-0432.CCR-06-3043 2-s2.0-34249810645
13. Chang Y.-S., Yeh K.-T., Hsu N. C., Lin S.-H., Chang T.-J., Chang J.-G., Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. Clinical Biochemistry 2010 43 3 296 301 10.1016/j.clinbiochem.2009.10.007 2-s2.0-74249119958
14. Yang M.-J., Hsu C.-K., Chang H.-J., Yen L.-C., Tsao D.-A., Chiu H.-H., Huang Y.-T., Chen Y.-F., Wang J.-Y., Lin S.-R., The KRAS mutation is highly correlated with EGFR alterations in patients with non-small cell lung cancer. Fooyin Journal of Health Sciences 2009 1 2 65 71 10.1016/S1877-8607(10)60002-1 2-s2.0-77649150158
15. Riely G. J., Marks J., Pao W., KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society 2009 6 2 201 205 10.1513/pats.200809-107LC 2-s2.0-65349107082
16. Jančík S., Drábek J., Radzioch D., Hajdúch M., Clinical relevance of KRAS in human cancers. Journal of Biomedicine and Biotechnology 2010 2010 13 150960 10.1155/2010/150960 2-s2.0-77954554630
17. Dienstmann R., De Dosso S., Felip E., Tabernero J., Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Molecular Oncology 2012 6 1 15 26 10.1016/j.molonc.2011.11.009 2-s2.0-84856266000
18. Soria J. C., Mok T. S., Cappuzzo F., Jänne P. A., EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treatment Reviews 2012 38 5 416 430 10.1016/j.ctrv.2011.10.003 2-s2.0-84861203302
19. Ulivi P., Calistri D., Zoli W., Amadori D., Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. Journal of Nucleic Acids Investigation 2010 1 1 47 54 10.4081/jnai.2010.e10 2-s2.0-78649919343
20. Stella G. M., Luisetti M., Inghilleri S., Cemmi F., Scabini R., Zorzetto M., Pozzi E., Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respiratory Medicine 2012 106 2 173 183 10.1016/j.rmed.2011.10.015 2-s2.0-84655167293
21. Hsu H.-F., Huang K.-H., Lu K.-J., Chiou S.-J., Yen J.-H., Chang C.-C., Houng J.-Y., Typhonium blumei extract inhibits proliferation of human lung adenocarcinoma A549 cells via induction of cell cycle arrest and apoptosis. Journal of Ethnopharmacology 2011 135 2 492 500 10.1016/j.jep.2011.03.048 2-s2.0-79955695767
22. Lai C. S., Mas R. H. M. H., Nair N. K., Mansor S. M., Navaratnam V., Chemical constituents and in vitro anticancer activity of Typhonium flagelliforme (Araceae). Journal of Ethnopharmacology 2010 127 2 486 494 10.1016/j.jep.2009.10.009 2-s2.0-73749084929
23. Lai C.-S., Mas R. H. M. H., Nair N. K., Majid M. I. A., Mansor S. M., Navaratnam V., Typhonium flagelliforme inhibits cancer cell growth in vitro and induces apoptosis: an evaluation by the bioactivity guided approach. Journal of Ethnopharmacology 2008 118 1 14 20 10.1016/j.jep.2008.02.034 2-s2.0-44149085620
24. Maurer T., Garrenton L. S., Oh A., Pitts K., Anderson D. J., Skelton N. J., Fauber B. P., Pan B., Malek S., Stokoe D., Ludlam M. J. C., Bowman K. K., Wu J., Giannetti A. M., Starovasnik M. A., Mellman I., Jackson P. K., Rudolph J., Wang W., Fang G., Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proceedings of the National Academy of Sciences of the United States of America 2012 109 14 5299 5304 10.1073/pnas.1116510109 2-s2.0-84859463451
25. Grant B. J., Lukman S., Hocker H. J., Sayyah J., Brown J. H., McCammon J. A., Gorfe A. A., Novel allosteric sites on ras for lead generation. PLoS ONE 2011 6 10 e25711 10.1371/journal.pone.0025711 2-s2.0-80055034617
26. Shima F., Yoshikawa Y., Ye M., Araki M., Matsumoto S., Liao J., Hu L., Sugimoto T., Ijiri Y., Takeda A., Nishiyama Y., Sato C., Muraoka S., Tamura A., Osoda T., Tsuda K.-I., Miyakawa T., Fukunishi H., Shimada J., Kumasaka T., Yamamoto M., Kataoka T., In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proceedings of the National Academy of Sciences of the United States of America 2013 110 20 8182 8187 10.1073/pnas.1217730110 2-s2.0-84877863454
27. Trott O., Olson A. J., Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2010 31 2 455 461 10.1002/jcc.21334 2-s2.0-76149120388
28. Ostrem J. M., Peters U., Sos M. L., Wells J. A., Shokat K. M., K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013 503 7477 548 551 10.1038/nature12796 2-s2.0-84888639050
29. Morris G. M., Goodsell D. S., Halliday R. S., Huey R., Hart W. E., Belew R. K., Olson A. J., Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 1998 19 14 1639 1662 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B 2-s2.0-11644261806
30. Morris G., Huey R., AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009 30 2785 2791
31. Huey R., Morris G. M., Forli S., Using AutoDock 4 and Vina with AutoDockTools: A Tutorial 2011
32. Seeliger D., de Groot B. L., Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of Computer-Aided Molecular Design 2010 24 5 417 422 10.1007/s10822-010-9352-6 2-s2.0-77953325845
33. ACD/ChemSketch, Version 12, Advanced Chemistry Development 2014 Toronto, Canada ACD/ChemSketch. http://www.acdlabs.com/
34. Mohan S., Abdul A. B., Abdelwahab S. I., Al-Zubairi A. S., Sukari M. A., Abdullah R., Elhassan Taha M. M., Ibrahim M. Y., Syam S., Typhonium flagelliforme induces apoptosis in CEMss cells via activation of caspase-9, PARP cleavage and cytochrome c release: its activation coupled with G0/G1 phase cell cycle arrest. Journal of Ethnopharmacology 2010 131 3 592 600 10.1016/j.jep.2010.07.043 2-s2.0-77956648432
35. Boriack-Sjodin P. A., Margarit S. M., Bar-Sagi D., Kuriyan J., The structural basis of the activation of Ras by Sos. Nature 1998 394 6691 337 343 10.1038/28548 2-s2.0-0032560850
36. Taveras A. G., Remiszewski S. W., Doll R. J., Cesarz D., Huang E. C., Kirschmeier P., Pramanik B. N., Snow M. E., Wang Y.-S., Del Rosario J. D., Vibulbhan B., Bauer B. B., Brown J. E., Carr D., Catino J., Evans C. A., Girijavallabhan V., Heimark L., James L., Liberles S., Nash C., Perkins L., Senior M. M., Tsarbopoulos A., Ganguly A. K., Aust R., Brown E., Delisle D., Fuhrman S., Hendrickson T., Kissinger C., Love R., Sisson W., Villafranca E., Webber S. E., Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorganic and Medicinal Chemistry 1997 5 1 125 133 10.1016/S0968-0896(96)00202-7 2-s2.0-0031012426